Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.89
RPTP's Cash to Debt is ranked lower than
72% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. RPTP: 1.89 )
Ranked among companies with meaningful Cash to Debt only.
RPTP' s 10-Year Cash to Debt Range
Min: 0.96  Med: 1851.76 Max: No Debt
Current: 1.89
Equity to Asset 0.46
RPTP's Equity to Asset is ranked lower than
73% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RPTP: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
RPTP' s 10-Year Equity to Asset Range
Min: -1.88  Med: 0.71 Max: 0.98
Current: 0.46
-1.88
0.98
F-Score: 3
Z-Score: 3.65
M-Score: -1.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -51.62
RPTP's Operating margin (%) is ranked higher than
53% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. RPTP: -51.62 )
Ranked among companies with meaningful Operating margin (%) only.
RPTP' s 10-Year Operating margin (%) Range
Min: -5100  Med: -297.83 Max: -57.63
Current: -51.62
-5100
-57.63
Net-margin (%) -69.06
RPTP's Net-margin (%) is ranked higher than
50% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. RPTP: -69.06 )
Ranked among companies with meaningful Net-margin (%) only.
RPTP' s 10-Year Net-margin (%) Range
Min: -5000  Med: -297.54 Max: -75.6
Current: -69.06
-5000
-75.6
ROE (%) -122.44
RPTP's ROE (%) is ranked lower than
84% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. RPTP: -122.44 )
Ranked among companies with meaningful ROE (%) only.
RPTP' s 10-Year ROE (%) Range
Min: -2769.55  Med: -113.35 Max: -18.3
Current: -122.44
-2769.55
-18.3
ROA (%) -33.48
RPTP's ROA (%) is ranked lower than
55% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. RPTP: -33.48 )
Ranked among companies with meaningful ROA (%) only.
RPTP' s 10-Year ROA (%) Range
Min: -158.44  Med: -72.77 Max: -15.91
Current: -33.48
-158.44
-15.91
ROC (Joel Greenblatt) (%) -554.72
RPTP's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. RPTP: -554.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RPTP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -43756.47  Med: -5656.12 Max: -350.25
Current: -554.72
-43756.47
-350.25
EBITDA Growth (3Y)(%) -19.70
RPTP's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. RPTP: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RPTP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -83.1  Med: -6.10 Max: 91.8
Current: -19.7
-83.1
91.8
EPS Growth (3Y)(%) -10.30
RPTP's EPS Growth (3Y)(%) is ranked lower than
54% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. RPTP: -10.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RPTP' s 10-Year EPS Growth (3Y)(%) Range
Min: -86.8  Med: -3.40 Max: 97
Current: -10.3
-86.8
97
» RPTP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RPTP Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
» More
Q3 2014

RPTP Guru Trades in Q3 2014

Joel Greenblatt 22,595 sh (New)
Steven Cohen 418,500 sh (New)
» More
Q4 2014

RPTP Guru Trades in Q4 2014

Joel Greenblatt Sold Out
Steven Cohen Sold Out
» More
Q2 2015

RPTP Guru Trades in Q2 2015

Paul Tudor Jones 31,982 sh (New)
Joel Greenblatt 18,396 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RPTP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.14
RPTP's P/B is ranked lower than
74% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. RPTP: 8.14 )
Ranked among companies with meaningful P/B only.
RPTP' s 10-Year P/B Range
Min: 0.3  Med: 8.74 Max: 43
Current: 8.14
0.3
43
P/S 9.79
RPTP's P/S is ranked higher than
50% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. RPTP: 9.79 )
Ranked among companies with meaningful P/S only.
RPTP' s 10-Year P/S Range
Min: 0.42  Med: 10.87 Max: 185.57
Current: 9.79
0.42
185.57
Current Ratio 6.89
RPTP's Current Ratio is ranked higher than
64% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. RPTP: 6.89 )
Ranked among companies with meaningful Current Ratio only.
RPTP' s 10-Year Current Ratio Range
Min: 0.39  Med: 4.96 Max: 150.34
Current: 6.89
0.39
150.34
Quick Ratio 6.74
RPTP's Quick Ratio is ranked higher than
64% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. RPTP: 6.74 )
Ranked among companies with meaningful Quick Ratio only.
RPTP' s 10-Year Quick Ratio Range
Min: 0.39  Med: 4.96 Max: 150.34
Current: 6.74
0.39
150.34
Days Inventory 216.08
RPTP's Days Inventory is ranked lower than
75% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. RPTP: 216.08 )
Ranked among companies with meaningful Days Inventory only.
RPTP' s 10-Year Days Inventory Range
Min: 235.18  Med: 283.20 Max: 331.22
Current: 216.08
235.18
331.22
Days Sales Outstanding 56.65
RPTP's Days Sales Outstanding is ranked higher than
55% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. RPTP: 56.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
RPTP' s 10-Year Days Sales Outstanding Range
Min: 0.78  Med: 31.35 Max: 1095
Current: 56.65
0.78
1095

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.25
RPTP's Price/Net Cash is ranked lower than
67% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. RPTP: 12.25 )
Ranked among companies with meaningful Price/Net Cash only.
RPTP' s 10-Year Price/Net Cash Range
Min: 0.94  Med: 6.22 Max: 260.4
Current: 12.25
0.94
260.4
Price/Net Current Asset Value 9.55
RPTP's Price/Net Current Asset Value is ranked lower than
61% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. RPTP: 9.55 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RPTP' s 10-Year Price/Net Current Asset Value Range
Min: 0.93  Med: 6.96 Max: 231
Current: 9.55
0.93
231
Price/Tangible Book 8.54
RPTP's Price/Tangible Book is ranked lower than
69% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. RPTP: 8.54 )
Ranked among companies with meaningful Price/Tangible Book only.
RPTP' s 10-Year Price/Tangible Book Range
Min: 0.86  Med: 7.60 Max: 113.5
Current: 8.54
0.86
113.5
Price/Median PS Value 0.90
RPTP's Price/Median PS Value is ranked higher than
57% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. RPTP: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
RPTP' s 10-Year Price/Median PS Value Range
Min: 0.05  Med: 1.02 Max: 173.6
Current: 0.9
0.05
173.6
Earnings Yield (Greenblatt) (%) -4.68
RPTP's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. RPTP: -4.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RPTP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -4.68  Med: 287.15 Max: 22393.9
Current: -4.68
-4.68
22393.9

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 97 125 141
EPS($) -0.74 -0.40 -0.27
EPS without NRI($) -0.74 -0.40 -0.27

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:XYXR.Germany,
Raptor Pharmaceutical Corp was initially incorporated in Nevada on July 29, 1997 as Axonyx Inc. In October 2006, Axonyx Inc. and its then wholly-owned subsidiary completed a reverse merger, business combination with TorreyPines Therapeutics, Inc., reincorporated in Delaware and changed the corporate name to 'TorreyPines Therapeutics, Inc. On September 28, 2009, the Company name was again changed from TorreyPines Therapeutics, Inc., to Raptor Pharmaceutical Corp. The Company is a biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company's product, PROCYSBI cysteamine bitartrate, delayed-release capsules received marketing approval from the U.S. Food and Drug Administration on April 30, 2013 for the management of nephropathic cystinosis in adults and children six years and older. The European equivalent, PROCYSBI gastro-resistant hard capsules of cysteamine, received marketing authorization on September 6, 2013 from the European Commission, as an orphan medicinal product for the management of proven nephropathic cystinosis for marketing in the European Union. PROCYSBI received 7 years and 10 years of market exclusivity as an orphan drug in the U.S. and the EU, respectively. PROCYSBI is an approved therapy for the management of nephropathic cystinosis, a rare, life-threatening metabolic lysosomal storage disorder that causes the rapid, toxic accumulation of cystine in all cells, tissues and organs in the body. PROCYSBI capsules contain cysteamine bitartrate in the form of innovative microspheronized beads that are individually coated to create delayed and extended-release properties, allowing patients to maintain consistent therapeutic systemic drug levels over a 12-hour dosing period. Cysteamine is a highly-reactive molecule generated in the cell during the metabolism of cysteine. The Company's pipeline products include; its proprietary delayed-release form of cysteamine, or RP103. The Company currently has product candidates in clinical development designed to potentially treat Huntington's disease, Non-alcoholic fatty liver disease, Leigh syndrome and other mitochondrial disorders and aldehyde dehydrogenase deficiency. The Company's preclinical programs are based upon bioengineered novel drug candidates that are designed to target cancer and other diseases. Its other clinical-stage product candidates include: Convivia its proprietary oral formulation of 4-methylpyrazole, for the potential management of acetaldehyde toxicity due to alcohol consumption by individuals with aldehyde dehydrogenase, or ALDH2, deficiency, an inherited metabolic disorder. With respect to any of the Company's product candidates for which it obtain FDA approval, it will be subject to ongoing FDA obligations and continued regulatory review, which may result in significant additional expense.
» More Articles for RPTP

Headlines

Articles On GuruFocus.com
My Portfolio Jan 21 2015 
comment on RPTP Mar 15 2013 

More From Other Websites
Raptor Pharmaceutical Makes an Acquisition Aug 25 2015
Raptor Pharmaceuticals (RPTP) in Focus: Stock Adds 5.8% Aug 24 2015
Raptor (RPTP) to Buy Quinsair, Boost Rare Disease Portfolio Aug 21 2015
RAPTOR PHARMACEUTICAL CORP Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 21 2015
Raptor Pharma Stock Up After Cystic Fibrosis Deal Aug 21 2015
Raptor Pharmaceuticals Acquires Rights to QuinsairTM Aug 21 2015
Raptor Pharmaceuticals Buys Quinsair: What You Need To Know Aug 21 2015
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM) Aug 21 2015
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM) Aug 20 2015
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM) Aug 20 2015
Raptor Pharmaceutical Voted a "Best Places to Work" Company in the North San Francisco Bay Area Aug 20 2015
Raptor Pharmaceutical Voted a "Best Places to Work" Company in the North San Francisco Bay Area Aug 20 2015
RAPTOR PHARMACEUTICAL CORP Financials Aug 18 2015
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged... Aug 17 2015
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged... Aug 17 2015
Coverage initiated on Raptor Pharma by FBR Capital Aug 11 2015
10-Q for Raptor Pharmaceutical Corp. Aug 08 2015
Edited Transcript of RPTP earnings conference call or presentation 6-Aug-15 8:30pm GMT Aug 07 2015
Raptor Pharmaceutical reports 2Q loss Aug 06 2015
Raptor Pharmaceutical reports 2Q loss Aug 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK